Studies have shown that the EGFR signaling pathway is likely to accelerate VPI development through its downstream effector microRNA-135b (35), so whether the difference in targeted therapy may affect the survival rate of NSCLC patients with VPI needs further study. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.